About Us: Artera is a leading precision medicine company developing AI tests to personalize cancer therapy. Artera offers an AI-enabled test that is the first of its kind to provide both predictive and prognostic results for patients with localized prostate cancer: ArteraAI Prostate Test.
Artera’s multimodal artificial intelligence (MMAI) biomarker test leverages a unique algorithm that assesses digital images from a patient’s biopsy and learns from a patient’s clinical data. The ArteraAI test combines this information to determine prognosis and predict whether a patient will benefit from a particular therapy. The test has been validated using many Phase 3 randomized trials yielding level 1B evidence and inclusion within the NCCN guidelines.
The Medical Science Liaison - KOL Management (MSL) is a field-based professional with scientific and clinical expertise who would be responsible for providing medical and scientific education on Artera’s AI-based prostate cancer biomarker test, new products, and our portfolio in development. The MSL/Sr. MSL engages in scientific exchange with Key Opinion Leaders and Healthcare Professionals consistent with Medical Affairs and company objectives.